Description

Kainova Therapeutics is a clinical-stage biopharmaceutical company, headquartered in Montreal, Canada, driving a robust pipeline of breakthrough therapies that precisely modulate G protein-coupled receptors (GPCRs) to transform patient outcomes, particularly in immuno-oncology and inflammation. Kainova’s key programs include a unique clinical-stage Treg-depleting anti-CCR8 antibody with differentiated competitive features and a first-in-class pre-IND stage biased antagonist of PAR2.

By unlocking challenging and unexploited GPCR targets through its validated approach that integrates deep biological knowledge, Kainova delivers highly differentiated therapies designed to address unmet medical needs and improve therapeutic efficacy. Grounded in scientific excellence and recognized for a solid track record of collaborations with major pharma, physicians and KOLs worldwide, Kainova creates long-term value in competitive and fast-expanding markets.

Operating in North America, France and Australia, Kainova is progressing with clinical momentum towards global commercialization. As GPCRs gain renewed attention as next-generation drug targets, Kainova is uniquely positioned to lead the field, combining deep biological insight with commercial maturity to drive global impact.

 
Back to list